View Future GrowthBlack Bird Biotech 過去の業績過去 基準チェック /06Black Bird Biotechの過去数年間の業績に関するデータが不十分です。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 業界の成長5.95%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報30 Sep 2023最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • May 18Black Bird Biotech, Inc. announced delayed 10-Q filingOn 05/16/2024, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 17+ 1 more updateBlack Bird Biotech, Inc. Appoints Nelson Grist as New CEOBlack Bird Biotech, Inc. announced that it has appointed public markets veteran Nelson Grist as its Chief Executive Officer (CEO). With over 15 years of experience in executive positions at publicly traded companies focused on emerging technologies in a variety of industries, Grist seeks to expand the Company’s strategic growth plan beyond its current agricultural offerings into burgeoning verticals such as innovative wellness and healthcare solutions through both organic growth and M&A activities. Mr. Grist has over 15 years’ experience serving in a Chief Executive Officer role at multiple publicly-traded companies focused on the health and wellness sector. Beyond his leadership roles in capital markets, Mr. Grist has extensive experience as a global CPG (customer packaged goods) and direct selling industry executive with progressive international leadership and general management experience across North America, Latin America, and Europe. He is a proven transformational leader, strategic thinker, and change agent, with a track record of creating shareholder value through profitable growth, brand development, performance improvement and team building. Mr. Grist’s experience also extends into the areas of P&L management, organizational design, consumer marketing, commercial capability enhancement, supply chain, talent development, and bringing cross-functional work groups together with a common goal to produce outstanding results.お知らせ • Apr 02Black Bird Biotech, Inc. announced delayed annual 10-K filingOn 04/01/2024, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 11/15/2023, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 16Black Bird Biotech, Inc. announced delayed 10-Q filingOn 05/15/2023, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 08/16/2022, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 05/16/2022, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 13William J. Lobell Appoints as Executive Vice President of Sales and Development for Black Bird Biotech, IncOn April 7, 2022, William J. LoBell was appointed as Executive Vice President of Sales and Development for Black Bird Biotech, Inc. From December 2021 until April 2022, Mr. LoBell served as a consultant to Barry's Restore It All Products.お知らせ • Apr 01Black Bird Biotech, Inc. announced delayed annual 10-K filingOn 03/31/2022, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 08/16/2021, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 18Digital Development Partners, Inc. announced delayed 10-Q filingOn 05/17/2021, Digital Development Partners, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Digital Development Partners, Inc. announced delayed annual 10-K filingOn 03/31/2021, Digital Development Partners, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Feb 10Digital Development Partners, Inc. Obtains Exclusive Worldwide Distribution Rights and 80% Reduction in Royalty Rate to Disruptive EPA Registered Plant-Based Biopesticide MiteXstreamDigital Development Partners, Inc. announced that it has obtained the exclusive worldwide distribution rights and an 80% reduction in the royalty rate to the disruptive plant-based biopesticide MiteXstream, an effective eradicator of spider mites, a pest that destroys crops, especially cannabis, hops, coffee, and house plants, as well as molds and mildew. Spider Mites are an industry wide issue. In fact, in addition to cannabis, spider mites are a significant pest in the production of hemp and hops, among other agricultural products. MiteXstream eliminates spider mites and their eggs, with no risk of plant damage. Based upon independent lab testing, users of MiteXstream are able to treat their cannabis plants through the day of harvest and still satisfy state-level pesticide testing standards, creating a tremendous competitive advantage, the MiteXstream secret sauce.お知らせ • Nov 17Digital Development Partners, Inc. announced delayed 10-Q filingOn 11/16/2020, Digital Development Partners, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 19Digital Development Partners, Inc. announced delayed 10-Q filingOn 08/18/2020, Digital Development Partners, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.収支内訳Black Bird Biotech の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:BBBT 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費30 Sep 230-10030 Jun 230-10031 Mar 230-11031 Dec 220-21030 Sep 220-22030 Jun 220-32031 Mar 220-22031 Dec 210-21030 Sep 210-11030 Jun 210-11031 Mar 210-11031 Dec 200-11030 Sep 20000030 Jun 20000031 Mar 20000031 Dec 190000質の高い収益: BBBTが 高品質の収益 を有しているかどうかを判断するにはデータが不十分です。利益率の向上: BBBTの 利益率 が過去 1 年間で改善したかどうかを判断するにはデータが不十分です。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: BBBTの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: BBBTの過去 1 年間の収益成長を 5 年間の平均と比較するにはデータが不十分です。収益対業界: BBBTの過去 1 年間の収益成長がPharmaceuticals業界平均を上回ったかどうかを判断するにはデータが不十分です。株主資本利益率高いROE: BBBTは現在利益が出ていないため、自己資本利益率 ( 0% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/26 17:02終値2026/05/21 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Black Bird Biotech, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 18Black Bird Biotech, Inc. announced delayed 10-Q filingOn 05/16/2024, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 17+ 1 more updateBlack Bird Biotech, Inc. Appoints Nelson Grist as New CEOBlack Bird Biotech, Inc. announced that it has appointed public markets veteran Nelson Grist as its Chief Executive Officer (CEO). With over 15 years of experience in executive positions at publicly traded companies focused on emerging technologies in a variety of industries, Grist seeks to expand the Company’s strategic growth plan beyond its current agricultural offerings into burgeoning verticals such as innovative wellness and healthcare solutions through both organic growth and M&A activities. Mr. Grist has over 15 years’ experience serving in a Chief Executive Officer role at multiple publicly-traded companies focused on the health and wellness sector. Beyond his leadership roles in capital markets, Mr. Grist has extensive experience as a global CPG (customer packaged goods) and direct selling industry executive with progressive international leadership and general management experience across North America, Latin America, and Europe. He is a proven transformational leader, strategic thinker, and change agent, with a track record of creating shareholder value through profitable growth, brand development, performance improvement and team building. Mr. Grist’s experience also extends into the areas of P&L management, organizational design, consumer marketing, commercial capability enhancement, supply chain, talent development, and bringing cross-functional work groups together with a common goal to produce outstanding results.
お知らせ • Apr 02Black Bird Biotech, Inc. announced delayed annual 10-K filingOn 04/01/2024, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 11/15/2023, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 16Black Bird Biotech, Inc. announced delayed 10-Q filingOn 05/15/2023, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 08/16/2022, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 05/16/2022, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 13William J. Lobell Appoints as Executive Vice President of Sales and Development for Black Bird Biotech, IncOn April 7, 2022, William J. LoBell was appointed as Executive Vice President of Sales and Development for Black Bird Biotech, Inc. From December 2021 until April 2022, Mr. LoBell served as a consultant to Barry's Restore It All Products.
お知らせ • Apr 01Black Bird Biotech, Inc. announced delayed annual 10-K filingOn 03/31/2022, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 17Black Bird Biotech, Inc. announced delayed 10-Q filingOn 08/16/2021, Black Bird Biotech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 18Digital Development Partners, Inc. announced delayed 10-Q filingOn 05/17/2021, Digital Development Partners, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Digital Development Partners, Inc. announced delayed annual 10-K filingOn 03/31/2021, Digital Development Partners, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Feb 10Digital Development Partners, Inc. Obtains Exclusive Worldwide Distribution Rights and 80% Reduction in Royalty Rate to Disruptive EPA Registered Plant-Based Biopesticide MiteXstreamDigital Development Partners, Inc. announced that it has obtained the exclusive worldwide distribution rights and an 80% reduction in the royalty rate to the disruptive plant-based biopesticide MiteXstream, an effective eradicator of spider mites, a pest that destroys crops, especially cannabis, hops, coffee, and house plants, as well as molds and mildew. Spider Mites are an industry wide issue. In fact, in addition to cannabis, spider mites are a significant pest in the production of hemp and hops, among other agricultural products. MiteXstream eliminates spider mites and their eggs, with no risk of plant damage. Based upon independent lab testing, users of MiteXstream are able to treat their cannabis plants through the day of harvest and still satisfy state-level pesticide testing standards, creating a tremendous competitive advantage, the MiteXstream secret sauce.
お知らせ • Nov 17Digital Development Partners, Inc. announced delayed 10-Q filingOn 11/16/2020, Digital Development Partners, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 19Digital Development Partners, Inc. announced delayed 10-Q filingOn 08/18/2020, Digital Development Partners, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.